Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele |
| |
| Authors: | Monroy-García A Weiss-Steider B Hernández-Montes J Ortiz-Navarrete V F Bañuelos-Pánuco A Acosta-Araujo A Díaz-Quiñónez A López-Graniel C M Herbert G Granados J de Leo C Silva-López R M Mora-García M L |
| |
| Affiliation: | (1) Laboratorio de Inmunobiología (L-326), Unidad de Investigación en Diferenciación Celular y Cáncer, Facultad de Estudios Superiores Zaragoza, UNAM, Colonia Ejército de Oriente, México, MX;(2) Unidad de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, San Pedro Zacatenco, México, MX;(3) Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional. San Pedro Zacatenco, México, MX;(4) Departamento de Ginecología Oncológica, Instituto Nacional de Cancerología, Colonia Tlalpan, México, MX;(5) Departamento de Immunología y Reumatología, Instituto de Ciencias Médicas y de la Nutrición Salvador Zubirán, Colonia Tlalpan, México, MX;(6) Departamento de Transplantes, Instituto de Ciencias Médicas y de la Nutrición Salvador Zubirán, Colonia Tlalpan, México, MX;(7) Laboratorio de Inmunología Clínica, Instituto Nacional de Pediatría, Colonia Pedregal de San Angel, México, MX |
| |
| Abstract: | ![]()
Summary. In this work we present evidence that the homologous peptides IHSMNSTIL and IHSMNSSIL derived from L1 HPV-16 and 18 proteins respectively, and with high specificity for the allele HLA-B*3901, according with an algorithm prediction program, induced T cell stimulation in patients with advanced cervical cancer positive for HPV-16 or 18 infection and for the HLA-B*3901 allele. Interestingly, T lymphocytes derived from a patient with HPV-18 infection and stimulated with the peptide IHSMNSTIL were capable to kill a cervical cancer cell line named Rova, derived from the tumor of the same patient. In addition, the cytotoxic activity was strongly increased when this cell line was previously treated with hrIFN-γ. These results suggest that the CTL immune response to L1 HPV-16 and 18 protein derived epitopes is maintained in patients with advanced cervical cancer within specific alleles, and opens the possibility that homologous epitopes may be used in the generation of prophylactic vaccines for cervical tumors bearing different HPV-types. Received March 4, 2002; accepted May 20, 2002 |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
